Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 238

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 7
Chunk 238
---
73,059 ordinary shares, 15,000 warrants which are exercisable since April 27, 2015 (BSA 2015-1), 10,000 warrants which are exercisable since September 20, 2019 (BSA 2017).

(11) Consists of 660 ordinary shares, 14,200 warrants which are exercisable since July 1, 2015 (BSA 2015-2), 10,000 warrants which are exercisable since September 20, 2019 (BSA 2017).

(12) Consists of 50 ordinary shares.

(13) Consists of 1,000 ordinary shares and 8,260 warrants which are exercisable since October 3, 2024 (BSA 2022).

(14) Consists of 2,500 ordinary shares.

(15) Consists of 235,911 ordinary shares.

(16) Consists of 86,249 ordinary shares, 50 preferred shares 2016 which are convertible into 6,500 ordinary shares (AGAP 2016) and 10,000 redeemable warrants which are exercisable since July 1, 2015 (BSAAR 2015).

(17) Consists of 63,662 ordinary shares.

(18) Consists of 35,362 ordinary shares.

(19) Consists of 4,246 ordinary shares.

(20) Consists of 25,668 ordinary shares.

(21) Consists of 18,785 ordinary shares.

None of the principal shareholders has voting rights different than the other shareholders.

To the best of our knowledge, no other shareholder currently holds, directly or indirectly and acting alone or in concert, more than 5% of our share capital or voting rights. Furthermore, we believe that we are not directly or indirectly owned or controlled by another corporation or government, or by any other natural or legal persons. To our knowledge, there are no arrangements that may result in a change of control.

B. Related Party Transactions.

Since January 1, 2024, the Company has engaged in the following transactions with members of its Executive and Supervisory Boards and holders of more than 5% of its outstanding voting securities, and their respective affiliates, which Innate refers to as its related parties.

Arrangements with the Members of the Executive and Supervisory Boards

Director and Executive Officer Compensation

See “ Item 6B - Compensation - Limitations on Liability and